GeneDx Holdings: The Long View
What the filings say about its story, dilution and cash runway.
This page is information, not investment advice.
Sources used most:
- 10-K 2025, filed Feb 23, 2026
- 10-Q Q2 2026, filed Aug 3, 2026
- Q2 2026 results release, Aug 3, 2026
1. In one paragraph
Last updated Nov 12, 2026. Reflects the 10-K 2025 and the 10-Q for Q3 2026.
GeneDx runs a genetic-testing lab in Gaithersburg, Maryland that reads a patient’s exome (the protein-coding regions of genes) or whole genome (the complete DNA sequence) to diagnose rare genetic diseases, mostly in children. It books revenue when it delivers a result. Revenue from patients with third-party insurance was $345.2M, or 81% of the 2025 total; institutional customers (hospitals, clinics, state programmes and other labs) accounted for $70.1M (16%). In 2025 GeneDx had one reportable segment, with Fabric Genomics and Legacy Sema4 grouped in Other; from Q2 2026 all operations form a single segment (10-Q, note 15). 2025 revenue was $427.5M, up 40% (41% excluding revenue of the exited Legacy Sema4 business from 2024):
| 2025 (disclosed; shares are our calculation) | Revenue | Share of total |
|---|---|---|
| Exome and genome tests | $360.3M | 84% |
| Other gene panels | $50.9M | 12% |
| Data information | $7.5M | 2% |
| Hereditary cancer | $5.4M | 1% |
| Software and interpretation (Fabric Genomics) | $3.4M | 1% |
Sources: 10-K 2025 (segments, payor categories, revenue recognition); Q4 2025 release (product revenue).
2. Story so far
Last updated Nov 12, 2026. Reflects filings through Nov 9, 2026 and the Centers for Medicare & Medicaid Services (CMS) proposal of Sep 21, 2026.
In short: GeneDx listed in 2021 as Sema4, a loss-making genetics company, bought GeneDx in 2022 and then closed Sema4’s older testing businesses to focus on exome and genome tests, financed by heavy share issuance. It reached a profit on its own adjusted measure (which excludes items such as stock pay and depreciation) in late 2024, and generated positive cash flow from operations in 2025. In 2026 payments per test fell short of plan, the company cut its revenue guide, borrowed from Blackstone, and Medicare proposed lower 2027 rates for its main tests.
| Date | Milestone | Source |
|---|---|---|
| Jul 22, 2021 | Sema4 completes its merger with CM Life Sciences, a special-purpose acquisition company (a listed shell company); its shares start trading on Nasdaq the next day | 8-K |
| Apr 29, 2022 | ★ Buys GeneDx from OPKO Health for $150M cash plus 2.4M shares, funded partly by a $200M private share sale | 8-K, 10-K 2023 |
| 2022 | Announces exits from reproductive-health and somatic tumour testing; the Legacy Sema4 business was completely shut down in 2023 | 10-K 2025, notes 10 and 16 |
| Jan 31 and Apr 17, 2023 | Now renamed GeneDx Holdings (Jan 9), raises about $150M gross by selling 13.0M shares at $11.55 ($0.35 before the split); the last 0.68M shares are issued Apr 17 | 8-K, 10-K 2023 |
| Oct 30, 2023 | Cuts its 2023 revenue guide; announces a $50M Perceptive loan funded on Oct 27 | 8-K |
| Oct 29, 2024 | ★ Q3 2024: first adjusted net income ($1.2M), ahead of its 2025 target | Release |
| May 5, 2025 | Closes Fabric Genomics (artificial-intelligence interpretation software) for about $33.5M cash | 10-K 2025, note 3 |
| Jun 2025 | American Academy of Pediatrics recommends exome and genome sequencing as first-tier tests for children with developmental delay or intellectual disability | Q4 2025 release |
| Feb 27, 2026 | $100M Blackstone term loan; repays the Perceptive loan ($54.5M including a $4.0M prepayment premium) | 10-Q Q2 2026, note 8 |
| May 4, 2026 | ★ Cuts the 2026 revenue guide from $540–555M to $475–490M and records a $31.3M Fabric impairment (an accounting write-down) | Q1 2026 release |
| Jun 4, 2026 | First shareholder class action over statements about Fabric’s impact on the business | 10-Q Q2 2026, note 9 |
| Aug 3, 2026 | Q2 returns to adjusted net income ($0.4M); agrees an additional $50M Blackstone loan and a $5.0M share sale to Blackstone affiliates, both funded on Aug 7 | Release; 10-Q Q3 2026 |
| Sep 21, 2026 | ★ Medicare (CMS) publishes preliminary 2027 lab rates; cuts are limited to 15% a year through 2029. Reported: the main exome and genome codes are among those cut by the full 15% | CMS; reported by Discoveries in Health Policy |
| Nov 9, 2026 | Q3 revenue $123.1M, inside the guide, with $7.7M from changed estimates; test volume below the guide; 2026 volume and exome-revenue growth targets cut, adjusted net income target raised to about $12M | Q3 2026 release; 10-Q Q3 2026 |
| Oct 23, 2026 | Start of our coverage: GeneDx rose 135-fold on genome tests, then lost 66% on pay fears | WhyMyStockMoved |
3. Latest quarter: did the story change?
Last updated Nov 12, 2026. Reflects Q3 2026 (10-Q and release, Nov 9, 2026).
Bottom line: According to the Nov 9 release and 10-Q, Q3 revenue landed inside GeneDx’s own guide and adjusted net income beat it. But test volume fell short of the guide, and revenue included $7.7M from changed estimates for earlier quarters. GeneDx kept its 2026 revenue range while cutting its volume and exome-revenue growth targets. The August $50M Blackstone loan and $5.0M share sale were funded, lifting cash to $171.1M.
| Driver | Last quarter → this quarter | Management: before → now | Signal |
|---|---|---|---|
| Revenue | Q2 $114.4M → Q3 $123.1M (+5% from Q3 2025), including $7.7M from changes in estimates for earlier periods | Q3 guide $122–124M (Aug 3) → delivered $123.1M; 2026 guide $475–490M reiterated; Q4 guide $135M | Unchanged |
| Exome and genome volume | Q2 30,785 (+32%) → Q3 32,134 (+25%) | Q3 guide 33,200 (Aug 3) → delivered 32,134; 2026 volume growth at least 30% → at least 28%; Q4 guide 34,500 | Worse |
| Revenue per exome or genome test (our calculation)1 | Q2 $3,258 → Q3 $3,436; reported revenue includes favourable estimate revisions; about 10% below a year earlier on the release’s growth rates2 | 2026 exome and genome revenue growth at least 20% (Aug 3) → at least 17% (Nov 9) | Worse |
| Adjusted net income (company measure; excludes stock pay, depreciation and amortisation, interest, tax and other items) | Q2 +$0.4M → Q3 +$8.6M | Q3 guide about +$2M (Aug 3) → delivered +$8.6M; 2026 guide “positive” → about $12M; adjusted gross margin (revenue less service costs, excluding depreciation, amortisation, stock pay and restructuring, divided by revenue) about 70% → about 71% | Better |
| Cash, equivalents, marketable securities and restricted cash | Jun 30 $133.5M → Sep 30 $171.1M, after the $50M loan and $5.0M share sale were funded (Aug 7); term debt now $150.0M | Financing agreed, not yet confirmed (Aug 3) → funded (10-Q, Nov 9); minimum-liquidity covenant $75.0M | Better |
Sources: Q2 2026 release, Q3 2026 release, 10-Q Q2 2026, 10-Q Q3 2026.
Unresolved questions: whether payment per genome test recovers without one-off estimate changes; what Medicare’s final 2027 rates will be; and whether cash use slows enough to keep well clear of the loan’s $75.0M minimum-liquidity requirement.
4. Buybacks vs real dilution (5 years)
Last updated Nov 12, 2026. Reflects the equity statements in the 10-K 2023, 10-K 2025 and 10-Q Q3 2026.
Dilution in one line: Class A shares outstanding (the only class) rose 307% from Dec 31, 2021 to Sep 30, 2026, about 34.4% a year compounded. If you owned 1% of GeneDx at the end of 2021, you would own about 0.25% today without buying more (our calculation)3. None of the new shares were offset by buybacks. Our scale: High (over 3% a year).
Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.
Change in the period Total since Dec 31, 2021 Part year
Shares outstanding at period end (all classes): 7.4M on Dec 31, 2021, 30.0M on Sep 30, 2026, +307.4% (our calculation). A bar below zero means the count fell (net buybacks).
Class A common stock (the only class), adjusted for the 1-for-33 reverse split of May 2023, from the author's bridge (10-K and 10-Q equity statements).
| Period end | Shares outstanding | Change | Buybacks (fiscal year) | Stock-based pay (fiscal year) | Stock pay as % of revenue |
|---|---|---|---|---|---|
| 9M 2026 (Sep 30, 2026) | 30.0M | +2.4% | — | — | — |
| FY2025 (Dec 31, 2025) | 29.3M | +4.4% | — | $32M | 8% |
| FY2024 (Dec 31, 2024) | 28.0M | +7.9% | — | $9M | 3% |
| FY2023 (Dec 31, 2023) | 26.0M | +120.7% | — | −$0.3M | 0% |
| FY2022 (Dec 31, 2022) | 11.8M | +60.1% | — | $42M | 18% |
| FY2021 (Dec 31, 2021) | 7.4M | — | — | $219M | 103% |
Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.
Most new shares were sold for cash, above all in the January 2023 offering, which more than doubled the share count.
How we calculated this
| Bridge (millions of shares) | 2022 | 2023 | 2024 | 2025 | 9M 2026 | Total |
|---|---|---|---|---|---|---|
| Start of period | 7.35 | 11.77 | 25.98 | 28.02 | 29.25 | 7.35 |
| Stock pay, options and employee purchase plan | 0.48 | 0.48 | 0.57 | 0.83 | 0.62 | 2.98 |
| Share sales for cash | 1.52 | 12.99 | 0.83 | 0.40 | 0.08 | 15.81 |
| Acquisitions (GeneDx shares and a 2023 milestone payment to OPKO) | 2.42 | 0.70 | – | – | – | 3.13 |
| Warrant exercised (Perceptive’s right to buy shares, settled in stock) | – | – | 0.65 | – | – | 0.65 |
| Other (reverse-split rounding; subscription agreements) | – | 0.03 | – | – | 0.01 | 0.03 |
| Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| End of period | 11.77 | 25.98 | 28.02 | 29.25 | 29.95 | 29.95 |
Totals use unrounded filing figures, so components may not sum exactly.
Prices paid and received:
| Period | Shares bought back | Average price paid | Spent | Shares sold for cash | Average price received | Raised | Sources |
|---|---|---|---|---|---|---|---|
| 2022 | — | — | — | 1.52M | $132.00 (our calculation) | $200.0M | 10-K 2023: private placement with the GeneDx deal, 1,515,152 shares, $200M gross |
| 2023 | — | — | — | 12.99M | $11.55 (offering price; our calculation)4 | about $150.0M | 10-K 2023: public offering and direct offering, 12,992,620 shares, about $150M gross; prospectus |
| 2024 | — | — | — | 0.83M | $58.41 (company’s average) | $48.2M (our calculation) | 10-K 2025, note 15: 825,379 shares through an at-the-market programme (sales into the public market at prevailing prices) |
| 2025 | — | — | — | 0.40M | $121.68 (our calculation) | $48.5M (our calculation) | 10-K 2025, note 15: 251,367 shares at $106.56 and 147,583 at $147.44 at-the-market |
| 2026 to date (Jan 1–Sep 30) | — | — | — | 0.08M | $61.00 | $5.0M | 10-Q Q3 2026: 81,967 shares sold to Blackstone affiliates in a private placement that closed Aug 7, 2026; no at-the-market sales |
GeneDx sold shares for cash every year from 2022 to 2026, mostly in the 2022 private placement and the January 2023 offering, and has bought none back. Averages are derived (our calculation)5.
Basis and details
- Prices are per share and split-adjusted. Raised is gross proceeds before fees.
- GeneDx made no buybacks; its cash-flow statements show no shares withheld for employee taxes.
- Not counted as sales for cash: the 2024 Perceptive warrant exercise (settled in stock), acquisition shares, and 5,390 shares issued under “subscription agreements” in H1 2026 for $0.5M.
- For reference, Yahoo Finance reports a closing price of $51.87 on Nov 12, 2026 (historical prices).
| Stock-based pay | 2022 | 2023 | 2024 | 2025 | 9M 2026 |
|---|---|---|---|---|---|
| $M | 42.0 | −0.3 | 9.1 | 32.2 | 23.6 |
| % of revenue (our calculation)6 | 18% | 0% | 3% | 8% | 7% |
The 2023 figure is negative because GeneDx reversed $24.7M of earlier expense for awards forfeited when employees left (10-K 2023, stock-based compensation note).
5. Profit vs cash (latest FY and TTM)
Last updated Nov 12, 2026. Reflects the 10-K 2025, the 10-Q Q3 2026 and the company’s adjusted net income reconciliations.
GeneDx generated $14.3M of free cash flow (operating cash flow less capital spending) in 2025 but used $101.2M over the last 12 months, including $15.8M in Q3 2026 (our calculation)7.
| $M | 2025 | Trailing twelve months (TTM) to Sep 30, 2026 (our calculation)7 |
|---|---|---|
| Net income (loss) | −21.0 | −111.0 |
| Adjusted net income (company measure; TTM is the sum of the four quarters) | 41.8 | 5.2 |
| Operating cash flow | 33.3 | −75.1 |
| Capital spending (property, equipment and internal-use software) | −19.0 | −26.1 |
| Free cash flow (our calculation)8 | 14.3 | −101.2 |
The gap between net income and cash is mostly non-cash charges, plus cash tied up in working capital. Grouped by what each means for future profit and cash:
Helps future profit or cash:
- Receivables used $36.2M of cash in 2025: Revenue was recognised before collection; collecting these receivables would release cash, subject to reimbursement adjustments and collection risk.
Hurts future profit or cash:
- Stock pay ($32.2M in 2025, $23.6M in the first nine months of 2026), added back in both adjusted net income and operating cash flow: Not a cash cost, but it is a cost in profit and it adds shares (see section 4).
- Capital spending rose to $19.0M in 2025 from $5.5M in 2024, and was $21.8M in the first nine months of 2026: Cash spent on equipment and software is capitalised, then generally charged against profit through depreciation or amortisation over the assets’ useful lives.
- Depreciation and amortisation ($25.2M in 2025), added back in both adjusted net income and operating cash flow: A recurring non-cash charge that spreads past asset spending over later periods: it lowers profit each period, not cash.
- Interest on the $150.0M Blackstone term loan: net interest expense was $1.8M in Q3 2026 (10-Q Q3 2026).
Other reconciling items:
- A $31.3M non-cash impairment of Fabric goodwill and intangible assets in Q1 2026: It is in the TTM net loss but used no cash.
- A $6.6M loss on paying off the Perceptive loan early (Q1 2026): in the net loss.
- Q3 2026 revenue included $7.7M from changes in estimates for tests delivered in earlier periods, $6.7M more than a year earlier (10-Q Q3 2026).
The raw reconciling items
- A $31.3M non-cash impairment of Fabric goodwill and intangible assets in Q1 2026 is in the TTM net loss but used no cash.
- Stock pay ($32.2M in 2025) and depreciation and amortisation ($25.2M) are added back in both adjusted net income and operating cash flow.
- Working capital took cash. Receivables used $36.2M in 2025; in H1 2026 payables and other assets and liabilities used $32.6M.
- Capital spending rose to $19.0M in 2025 from $5.5M in 2024, and was $21.8M in the first nine months of 2026.
Funding: how long without new money? (our calculation; as of Sep 30, 2026, the latest filed balance sheet)
- Cash, cash equivalents and marketable securities of $170.1M covered about 1.7 years (about 7 quarters) of trailing-12-month free cash outflow of $101.2M (our calculation)9. The loan requires at least $75.0M of liquidity, so only about $95M is above that floor; the cash path below shows it quarter by quarter.
Funding details
- The further $50M Blackstone term loan and the $5.0M share sale agreed on Aug 3 were funded on Aug 7, 2026, and are in the Sep 30 cash (10-Q Q3 2026).
- Debt due within 24 months: none. The Blackstone term loan ($150.0M) is due in 2031 and requires minimum liquidity of $75.0M (10-Q Q3 2026).
- Undrawn credit lines: none disclosed.
- At-the-market share-sale programme: about $78.2M of capacity remained at Sep 30, 2026 (TD Cowen, agreed Oct 2025).
- GeneDx says its cash and marketable securities give it enough liquidity for at least 12 months from the 10-Q filing date (10-Q Q3 2026).
- This is based on past cash flow; spending plans can change it.
Extends the runway:
- None committed beyond the August financing, which is already in the cash.
Shortens the runway:
- The loan’s $75.0M minimum-liquidity requirement; the $4.8M Helo class-action settlement (stipulation signed July 2026), with no payment date disclosed.
Conditional:
- Fabric’s earned first milestone, still a $5.4M liability at Sep 30, payable in cash or stock; the second milestone remains possible, but GeneDx judged its revenue target unlikely to be met and valued it at zero; and the at-the-market programme, which depends on selling shares (about $78.2M of capacity).
Cash path (our calculation; an illustration, not a forecast):
At the past rate and with known items, cash would fall below zero in Q2 2028, and below the loan’s $75.0M minimum-liquidity level in Q3 2027; GeneDx itself says its cash covers at least 12 months from the Q3 10-Q filing (10-Q Q3 2026).
Illustration, not a forecast.
Ending cash (cash, equivalents and marketable securities) Known item Raising window (under a year of usual spending left) Would need new money
| Quarter | Starting cash | Usual spending | Known items | Ending cash | Sources / notes |
|---|---|---|---|---|---|
| Q4 2026 | +170.12 | −25.30 | 0.00 | +144.81 | The August Blackstone loan and share sale are in the starting cash |
| Q1 2027 | +144.81 | −25.30 | 0.00 | +119.51 | |
| Q2 2027 | +119.51 | −25.30 | 0.00 | +94.21 | Fabric milestones: $0 cash, because GeneDx may pay both in stock (second milestone: up to $7.5M by Apr 30, 2027; 10-Q Q3 2026) |
| Q3 2027 | +94.21 | −25.30 | 0.00 | +68.90 | Below the loan’s $75.0M minimum-liquidity level. Less than a year of usual spending left |
| Q4 2027 | +68.90 | −25.30 | 0.00 | +43.60 | Less than a year of usual spending left |
| Q1 2028 | +43.60 | −25.30 | 0.00 | +18.29 | Less than a year of usual spending left |
| Q2 2028 | +18.29 | −25.30 | 0.00 | −7.01 | Less than a year of usual spending left |
Amounts in $M.
At the past rate and with known items, cash would fall below zero in Q2 2028, and below the loan’s $75.0M minimum-liquidity level in Q3 2027; GeneDx itself says its cash covers at least 12 months from the Q3 10-Q filing (10-Q Q3 2026). Companies usually raise money well before that; quarters with less than a year of usual spending left are shaded.
What the cash path counts:
- Usual spending: −$25.30M a quarter, held flat.
- Known items: none counted. The Fabric milestones count as $0 cash because GeneDx may pay them in stock.
- Liquidity floor: cash would fall below the loan’s $75.0M minimum-liquidity level in Q3 2027.
How we calculated this
Amounts in $M to two decimals. Usual spending is trailing-12-month free cash flow (−$101.22M, Q4 2025–Q3 2026) ÷ 4 = −$25.30M a quarter, held flat. Starting cash is cash, cash equivalents and marketable securities at Sep 30, 2026 ($170.12M), without $0.99M of restricted cash. It already contains operating-lease payments, ordinary purchase commitments, interest and capital spending, so they are not added again. Not included:
- Finance-lease principal: payments total $2.045M in 2027 and $2.107M in 2028 including interest, but the principal share is not disclosed, so it is left out; it could bring the dates forward slightly (10-K, note 10).
- The $4.8M Helo class-action settlement; no payment date is disclosed.
Sources: 10-K 2025, 10-Q Q3 2026, Q4 2025, Q1 2026, Q2 2026 and Q3 2026 releases10.
6. Customer and contract exposure
Last updated Nov 12, 2026. Reflects the 10-K 2025 and the 10-Q Q3 2026.
GeneDx depends on health insurers and on government rates, not on any one customer.
| Payor groups at more than 10% of revenue (each combines several unnamed payors) | 2023 | 2024 | 2025 | 9M 2026 |
|---|---|---|---|---|
| Payor group A | 18% | 22% | 23% | 25% |
| Payor group B | 28% | 32% | 39% | 31% |
No single payor or individual client was more than 10% of revenue or receivables. The main exposures are the two payor groups above and Medicare’s 2027 lab rates, which CMS expects to finalise in November 2026.
Chart source11.
Payor, coverage, supplier and loan details
- No single payor or individual client accounted for more than 10% of revenue or receivables (10-K 2025, 10-Q).
- In its 2025 10-K, GeneDx said “a small percentage” of revenue came from Medicare (10-K 2025). Medicare rates still matter beyond Medicare: California’s Medicaid programme, for example, now pays 100% of the Medicare rate for genome sequencing (Q2 release). CMS expects to finalise 2027 rates in November 2026, effective Jan 1, 2027 (CMS).
- Coverage: 39 state Medicaid programmes cover outpatient exome or genome sequencing, and Carelon, which GeneDx calls the largest US lab benefit manager, began covering outpatient genome sequencing on Jun 14, 2026, opening access to up to 56 million covered lives (Q2 release).
- One unnamed supplier accounted for 20% of purchases in 2025 and 23% in the first nine months of 2026. All exome and genome tests are run in Gaithersburg (10-K 2025, 10-Q Q3 2026).
- The Blackstone loan ($150.0M) is secured by a first-priority lien on substantially all of GeneDx’s assets and may have to be repaid early on a change of control (10-Q Q3 2026).
7. What to watch
Last updated Nov 12, 2026. Reflects the Q3 2026 release and 10-Q (Nov 9) and the CMS Sep 21, 2026 proposal.
| Date | Item | Source |
|---|---|---|
| Nov 2026 (expected) | CMS final 2027 Medicare lab rates, including the exome and genome codes | CMS |
| Q4 2026 | Guide: revenue $135M, 34,500 exome and genome tests, $121M exome and genome revenue, adjusted gross margin at least 71%, adjusted net income about $12M | Q3 2026 release |
| Jan 1, 2027 | 2027 Medicare lab rates take effect | CMS |
| By Apr 30, 2027 | Fabric second milestone: up to $7.5M in cash or stock if Fabric’s 2026 revenue and margin targets are met | 10-Q Q3 2026 |
| Date not set | Court approval and payment of the $4.8M Helo settlement; the Fabric-related securities class actions (class period Apr 16, 2025 to May 4, 2026) | 10-Q Q3 2026 |
Valuation at each update
| Update | Close | Market value | EV | P/S | EV/sales | P/E | P/FCF | Revenue growth | FCF margin | Net cash (debt) | Basis |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | $56.15 (Oct 23) | $1.7B | $1.6B | 3.7× | 3.6× | n/m | n/m | +25% | −17% | $33M | 12 months to Jun 30, 2026 |
| Nov 12, 2026 | $51.87 (Nov 12) | $1.6B | $1.5B† | 3.4× | 3.3× | n/m | n/m | +15% | −22% | $24M† | 12 months to Sep 30, 2026 |
Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 9, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Nov 12, 2026: † Debt excludes finance-lease liabilities ($17.8M at Dec 31, 2025), which the Q3 10-Q doesn't report. Nov 12, 2026 price: official close, CNBC, Yahoo Finance.
Notes and calculations
-
Test revenue ÷ volume. ↩
-
Q2: $100.3M ÷ 30,785; Q3: $110.4M ÷ 32,134. Year-on-year change ≈ 1.12 ÷ 1.25 − 1 ≈ −10%, from the release’s +12% exome and genome revenue and +25% volume. ↩
-
Remaining ownership = 1% × 7.353M ÷ 29.954M ≈ 0.25%; growth = (29.954 ÷ 7.353 − 1) × 100 ≈ 307%; annual growth = [(29.954 ÷ 7.353)^(1 ÷ 4.75) − 1] × 100 ≈ 34.4%. End: 29,954,477 shares at Sep 30, 2026 (10-Q Q3 2026). ↩
-
$0.35 × 33. ↩
-
Gross proceeds ÷ shares. ↩
-
Stock-based compensation ÷ revenue × 100. ↩
-
2025 − 9M 2025 + 9M 2026 (10-K 2025, 10-Q Q3 2026): net loss −$21.0M + $3.4M − $93.4M; operating cash flow $33.3M − $36.4M − $72.0M; capital spending −$19.0M + $14.7M − $21.8M. Q3 2026 free cash flow: (−$72.0M + $61.4M) + (−$21.8M + $16.6M) = −$15.8M. ↩ ↩2
-
Operating cash flow + capital spending. ↩
-
($96.1M + $74.0M) = $170.1M; $170.1M ÷ $101.2M ≈ 1.7 years. ↩
-
TTM adjusted net income: $4.4M (Q4 2025) − $8.2M + $0.4M + $8.6M. ↩
-
Payor-concentration disclosures in the 10-K 2025 and 10-Q Q3 2026 (nine months to Sep 30). Each group combines several unnamed payors. ↩
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.
About GeneDx Holdings: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)